Pharmacology
-
When PH and ILD meet: From overlap to a unified disease paradigm
For clinicians, the shift in the PH-ILD space demands a broader perspective that integrates vascular and parenchymal disease, emphasizes early detection, and prioritizes multidisciplinary care.
-
Evolving biologic treatment options improving outcomes for patients with COPD
Farrukh Abbas, MD, FCCP, and Nicola Alexander Hanania, MD, MS, FCCP, explore the various treatment pathways—and the drugs targeting them—with the potential to reduce COPD exacerbations.
-
Varenicline sampling with minimal guidance may boost smoking cessation rates
According to the investigators, the medication sampling model may lower barriers to engagement and allow patients to consider cessation on their own terms.
-
Short-course all-oral therapy appears effective, safe for resistant TB
Patrick PJ Phillips, PhD, said the noninferiority BEAT Tuberculosis trial showed a six-month treatment strategy could achieve outcomes similar to those of longer, standard regimens.
-
Ensitrelvir cuts COVID-19 risk by two-thirds after household exposure
Paul E. Sax, MD, said postexposure prophylaxis may be a useful addition to vaccination, testing, and treatment, particularly in populations at high-risk of severe disease.
-
Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases
With the combination now available, Mark Jeng, MD, PhD, revisits positive results from a recent study evaluating the strategy in this high-risk population.
-
FDA warning on montelukast linked to prescription decline for asthma
Sami Hossri, MD, FCCP, said that while data show the warning prompted an immediate and sharp drop in new prescriptions, the shift in overall use was more modest.
-
First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC
Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.
-
TETON-1 treatment effects offer hope for patients with idiopathic pulmonary fibrosis
Christopher King, MD, FCCP, and Steven D. Nathan, MD, FCCP, discuss the clinical implications of inhaled treprostinil, including the medication’s potential use in future combination treatment strategies.
-
Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC
Coauthor Anup Kasi, MD, MPH, said the study represents an important step forward in the development of KRAS G12D-targeted therapies.
